|
James S. Manuso is president & chief executive officer of SuperGen, Inc., (NASDAQ: SUPG) and company with hematology-oncology products on the market and in development. Dr. Manuso currently serves on the boards of Novelos Therapeutics, Inc (OTCBB: NVLT) and Merrion Pharmaceuticals, Ltd. Most recently he served as president and CEO of Galenica Pharmaceuticals, Inc., a development stage company focused on cancer and infectious disease vaccines. Previously, he co-founded and was a general partner of PrimeTech Partners, a biotechnology venture management partnership, and managing general partner of the corporate advisory firm, The Channel Group, an international life sciences corporate advisory firm. Before co-founding PrimeTech Partners in 1998, Dr. Manuso was co-founder and president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. From 1974 until 1983, Dr. Manuso was an officer of The Equitable Companies, where he served as acting medical director and director of health care planning and development. Dr. Manuso earned a BA with honors in economics and chemistry from New York University, a PhD in experimental psychophysiology from The Graduate Faculty of the New School University, a certificate in healthcare management from Harvard Business School and an executive MBA from Columbia Business School. Dr. Manuso taught and lectured at Columbia, NYU, Georgetown University, Polytechnic University, and Waseda University (Japan). | 